Tempest Therapeutics, Inc. Sample Contracts
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 12th, 2025 • Tempest Therapeutics, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June , 2025, between Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
OVASCIENCE, INC. (a Delaware corporation) 5,000,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 6th, 2014 • OvaScience, Inc. • Pharmaceutical preparations • New York
Ovascience, Inc., a Delaware corporation (the “Company”), confirms its agreement with Leerink Partners LLC (“Leerink”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Leerink is acting as representative (in such capacity, the “Representative”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of Common Stock, par value $0.001 per share, of the Company (“Common Stock”) set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 750,000 additional shares of Common Stock. The aforesaid 5,000,000 shares of Common Stock (the “Initial Securities”) to be purchased by the Underwriters and all or a
OVASCIENCE, INC. 7,150,00 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • May 26th, 2016 • OvaScience, Inc. • Pharmaceutical preparations • New York
OvaScience, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 7,150,000 shares of Common Stock, par value $0.001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,072,500 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”. To the extent there are no additional Underwriters listed on Schedule 1 other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires.
FORM OF INDEMNIFICATION AGREEMENT(1)Indemnification Agreement • December 13th, 2018 • Millendo Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [ ], between Millendo Therapeutics, Inc., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”).
MILLENDO THERAPEUTICS, INC. and , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OFPreferred Stock Warrant Agreement • April 5th, 2019 • Millendo Therapeutics, Inc. • Pharmaceutical preparations • New York
PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between MILLENDO THERAPEUTICS, INC., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • June 20th, 2024 • Tempest Therapeutics, Inc. • Pharmaceutical preparations • New York
MILLENDO THERAPEUTICS, INC. and , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OFCommon Stock Warrant Agreement • April 5th, 2019 • Millendo Therapeutics, Inc. • Pharmaceutical preparations • New York
COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between MILLENDO THERAPEUTICS, INC., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
MILLENDO THERAPEUTICS, INC. and , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OFWarrant Agreement • April 5th, 2019 • Millendo Therapeutics, Inc. • Pharmaceutical preparations • New York
DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between MILLENDO THERAPEUTICS, INC., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
OVASCIENCE, INC. SALES AGREEMENTSales Agreement • November 3rd, 2016 • OvaScience, Inc. • Pharmaceutical preparations • New York
OvaScience, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
ContractWarrant Agreement • May 4th, 2021 • Millendo Therapeutics, Inc. • Pharmaceutical preparations • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
TEMPEST THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20[●] Debt SecuritiesIndenture • July 16th, 2021 • Tempest Therapeutics, Inc. • Pharmaceutical preparations • New York
INDENTURE, dated as of [●], 20[●] , among TEMPEST THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [TRUSTEE], as trustee (the “Trustee”):
Millendo Therapeutics, Inc. 4,166,667 Shares Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • December 5th, 2019 • Millendo Therapeutics, Inc. • Pharmaceutical preparations • New York
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • May 4th, 2021 • Millendo Therapeutics, Inc. • Pharmaceutical preparations
THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of January 15, 2021 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and TEMPEST THERAPEUTICS, INC., a Delaware corporation with offices located at 7000 Shoreline Court, Suite 275, South San Francisco, CA 94080 (“Borrower”), provides the terms on which the Lenders shall lend to Borrower and Borrower shall repay the Lenders. The parties agree as follows:
INDEMNIFICATION AGREEMENTIndemnification Agreement • April 11th, 2012 • OvaScience, Inc. • Delaware
THIS AGREEMENT (the “Agreement”) is made and entered into as of between OvaScience, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • July 5th, 2012 • OvaScience, Inc. • In vitro & in vivo diagnostic substances • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is made as of the 29th day of March, 2012, by and among OvaScience, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
LEASE AGREEMENTLease Agreement • May 4th, 2021 • Millendo Therapeutics, Inc. • Pharmaceutical preparations
THIS LEASE AGREEMENT (this “Lease”) is made this 22nd day of February 2019, between ARE-SAN FRANCISCO NO. 17, LLC, a Delaware limited liability company (“Landlord”), and TEMPEST THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
Millendo Therapeutics, Inc. $50,000,000 Shares Common Stock ($0.001 par value) Equity Distribution AgreementEquity Distribution Agreement • April 5th, 2019 • Millendo Therapeutics, Inc. • Pharmaceutical preparations • New York
Millendo Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Citigroup Global Markets Inc. (the “Manager”) as follows:
PREFUNDED COMMON STOCK PURCHASE WARRANT TEMPEST THERAPEUTICS, INC.Prefunded Common Stock Purchase Warrant • June 12th, 2025 • Tempest Therapeutics, Inc. • Pharmaceutical preparations
THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”), to subscribe for and purchase from Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
OVASCIENCE, INC. Nonstatutory Stock Option Agreement Granted Under 2011 Stock Incentive PlanNonstatutory Stock Option Agreement • May 17th, 2012 • OvaScience, Inc. • In vitro & in vivo diagnostic substances
OVASCIENCE, INC. Incentive Stock Option Agreement Granted Under 2012 Stock Incentive PlanIncentive Stock Option Agreement • May 17th, 2012 • OvaScience, Inc. • In vitro & in vivo diagnostic substances
DIRECTOR AND OFFICER INDEMNIFICATION AGREEMENTIndemnification Agreement • July 7th, 2021 • Tempest Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is entered into as of the day of , , by and between Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
OVASCIENCE, INC. Restricted Stock Agreement Granted Under 2011 Stock Incentive PlanRestricted Stock Agreement • April 11th, 2012 • OvaScience, Inc. • Delaware
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 26th, 2025 • Tempest Therapeutics, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of November 24, 2025, between Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
RIGHTS AGREEMENT October 10, 2023Rights Agreement • October 11th, 2023 • Tempest Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS RIGHTS AGREEMENT (this “Agreement”) is dated as of October 10, 2023 (the “Agreement Date”) and is made between TEMPEST THERAPEUTICS, INC., a Delaware corporation (the “Company”), and COMPUTERSHARE TRUST COMPANY, N.A, as rights agent (“Rights Agent”).
LEASE AGREEMENTLease Agreement • May 17th, 2012 • OvaScience, Inc. • In vitro & in vivo diagnostic substances
THIS LEASE AGREEMENT (this “Lease”) is made this 1st day of May, 2012, between ARE-MA REGION NO. 38, LLC, a Delaware limited liability company (“Landlord”), and OVASCIENCE, INC., a Delaware corporation (“Tenant”).
OVASCIENCE, INC. Amended and Restated Restricted Stock AgreementRestricted Stock Agreement • April 11th, 2012 • OvaScience, Inc. • Delaware
AGREEMENT made this 29th day of March, 2012, between OvaScience, Inc., a Delaware corporation (the “Company”), Richard Aldrich (“Aldrich”) and the Richard H. Aldrich Irrevocable Trust of 2011 (the “Trust”, and, together with Aldrich, the “Founder”) . This agreement amends and restates in its entirety the Restricted Stock Agreement, dated April 7, 2011, between the Company (formerly known as Ovastem, Inc.) and Aldrich (the “Prior Restricted Stock Agreement”). In connection with the transfer of shares of stock subject to the Prior Restricted Stock Agreement from Aldrich to the Trust on December 30, 2011, the Trust agreed to become party to and bound by the Prior Restricted Stock Agreement.
Nonstatutory Stock Option AgreementNonstatutory Stock Option Agreement • May 3rd, 2018 • OvaScience, Inc. • Pharmaceutical preparations • Delaware
Re: Amended and Restated Employment Terms Dear Jen:Employment Agreement • March 29th, 2021 • Millendo Therapeutics, Inc. • Pharmaceutical preparations
Millendo Therapeutics US, Inc. (the “Company”) desires to amend and restate the terms of your employment in connection with your appointment as Chief Financial Officer of the Company pursuant to the terms of this letter (the “Agreement”). Subject to your execution of this Agreement, effective as of February 1, 2021 (the “Effective Date”) this Agreement amends, restates and supersedes in its entirety your Employment Terms with Millendo Therapeutics US, Inc. effective January 1, 2019 (the “Prior Agreement”).
AGREEMENT AND PLAN OF MERGERMerger Agreement • March 29th, 2021 • Millendo Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of March 29, 2021, is entered into by and among Millendo Therapeutics, Inc., a Delaware corporation (“Public Company”); Mars Merger Corp., a Delaware corporation and a wholly owned subsidiary of Public Company (the “Merger Sub”); and Tempest Therapeutics, Inc., a Delaware corporation (“Merger Partner”).
Millendo Therapeutics, Inc. $50,000,000 Shares Common Stock ($0.001 par value) Amended and Restated Equity Distribution AgreementEquity Distribution Agreement • March 4th, 2020 • Millendo Therapeutics, Inc. • Pharmaceutical preparations • New York
Reference is made to the Equity Distribution Agreement dated April 5, 2019 (the “Original Equity Distribution Agreement”) by and between Millendo Therapeutics, Inc., a Delaware corporation (the “Company”), and Citigroup Global Markets Inc. (“Citigroup”), pursuant to which the Company agreed, in its sole discretion, to issue and sell, from time to time, through Citigroup, as sales agent, shares of the Company’s common stock, par value $0.001 per share, having an aggregate offering price of up to $50,000,000 (the “Shares”). The Company, Citigroup and SVB Leerink LLC (“SVB Leerink”) (together with Citigroup, collectively, the “Managers”, and each individually a “Manager”) wish to amend and restate the Original Equity Distribution Agreement in its entirety as provided hereby.
TEMPEST THERAPEUTICS, INC. South San Francisco, California 94080Executive Employment Agreement • April 30th, 2025 • Tempest Therapeutics, Inc. • Pharmaceutical preparations
This Agreement supersedes, amends and restates in all respects all prior agreements and understandings between you and the Company regarding the subject matter herein. The date on which you sign this Agreement is referred to herein as the “Effective Date”.
Tempest Therapeutics, Inc. Brisbane, California 94005Executive Employment Agreement • March 27th, 2025 • Tempest Therapeutics, Inc. • Pharmaceutical preparations
This Agreement supersedes, amends and restates in all respects all prior agreements and understandings between you and the Company regarding the subject matter herein. The date on which you sign this Agreement is referred to herein as the “Effective Date”.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 23rd, 2026 • Tempest Therapeutics, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of March 20, 2026, between Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
June 13, 2025 Stephen R. Brady Re: Separation Agreement Dear Steve:Separation Agreement • August 11th, 2025 • Tempest Therapeutics, Inc. • Pharmaceutical preparations
This letter sets forth the substance of the separation agreement (the “Agreement”) that Tempest Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 2nd, 2022 • Tempest Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April 26, 2022, by and among Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on Schedule 1 hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). In the event that there is only a single Purchaser, then all references herein to Purchasers shall be deemed to refer to such Purchaser.